Compare MTW & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTW | DBVT |
|---|---|---|
| Founded | 1902 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 749.4M | 850.9M |
| IPO Year | 1994 | 2014 |
| Metric | MTW | DBVT |
|---|---|---|
| Price | $22.15 | $8.92 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $14.00 | ★ $38.55 |
| AVG Volume (30 Days) | ★ 426.0K | 338.0K |
| Earning Date | 11-04-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $2,240,900,000.00 | $5,636,000.00 |
| Revenue This Year | $3.43 | N/A |
| Revenue Next Year | $1.55 | $1,630.16 |
| P/E Ratio | $101.64 | ★ N/A |
| Revenue Growth | 2.89 | ★ 35.77 |
| 52 Week Low | $9.93 | $8.86 |
| 52 Week High | $24.00 | $26.19 |
| Indicator | MTW | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 23.59 |
| Support Level | $11.79 | N/A |
| Resistance Level | $23.59 | $14.90 |
| Average True Range (ATR) | 0.94 | 0.47 |
| MACD | -0.18 | -0.14 |
| Stochastic Oscillator | 38.14 | 0.12 |
Manitowoc Co Inc provides engineered lifting solutions. It designs and manufactures mobile telescopic cranes, tower cranes, lattice-boom crawler cranes, and boom trucks. It offers products under brand names such as Grove, Manitowoc, National Crane, Potain, Shuttlelift, and Manitowoc Crane Care. Its crane products serve dealers, rental companies, contractors, and government entities in diverse markets, including energy production/distribution and utility, petrochemical and industrial, infrastructure, and commercial/residential construction. Manitowoc has three reportable segments: the Americas, Europe and Africa, and the Middle East and Asia-Pacific. The Americas segment generates the majority of the revenue for the company.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.